Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
Birahim Pierre Ndiaye,Friedrich Thienemann,Martin Ota,Bernard S Landry,Makhtar Camara,Siry Dièye,Tandakha Ndiaye Dieye,Hanif Esmail,Rene Goliath,Kris Huygen,Vanessa January,Ibrahima Ndiaye,Tolu Oni,Michael Raine,Marta Romano,Iman Satti,Sharon Sutton,Aminata Thiam,Katalin A Wilkinson,Souleymane Mboup,Robert J Wilkinson,Helen McShane,MVA85A 030 trial investigators,Margaret Anne Snowden,J Bruce McClain,Barbara Shepherd,Ndèye Fatou Ngom,Ibrahima Sow,Mamadou Gueye,Papa Salif Sow,Yolande Harley,Thelma Leopeng,Phila Mawu,Relebohile Tsekela,Andiswa Beatrice Vasi,Nobantu Jack,Ida Oliphant,Patricia Rini,Fadheela Patel,Kerryn Matthews,Melina Carr,Nonzwakazi Bangani,Zeinonisaa Latief,Patrick Hamadi,Raylene Titus,Antoneta Mashinyira,Nomvula Makade,Amanda Jackson,Lorraine Swanepoel,Nashreen Omar-Davies,Derval Reidy,Abongile Makuluma,Marianne Skreden,Nolitha Qondisa Qina,Modou Seck,Allé Baba Dieng,Awa Ba,Abdou Padane,Khady Joséphine Badiane,Ndèye Salimata Santos,Ndèye Coumba Touré,Halimatou Diop,Ousmane Diouf,Mouhamedou Ndiaye,Aminata Dia,Tidiane Siby,Aliou Niang,Mamadou Diarrha Bèye,Papa Ibrahima Ndiaye,Sada Diallo,Ousseynou Ndiaye,Aliou Sène,Ameth Boly Niang,Awa Ndiaye,Mame Yacine Fall,Marema Fall,Sam Vermaak,Alison Lawrie,Kristin Griffiths
DOI: https://doi.org/10.1016/S2213-2600(15)00037-5
Abstract:Background: HIV-1 infection is associated with increased risk of tuberculosis and a safe and effective vaccine would assist control measures. We assessed the safety, immunogenicity, and efficacy of a candidate tuberculosis vaccine, modified vaccinia virus Ankara expressing antigen 85A (MVA85A), in adults infected with HIV-1. Methods: We did a randomised, double-blind, placebo-controlled, phase 2 trial of MVA85A in adults infected with HIV-1, at two clinical sites, in Cape Town, South Africa and Dakar, Senegal. Eligible participants were aged 18-50 years, had no evidence of active tuberculosis, and had baseline CD4 counts greater than 350 cells per μL if they had never received antiretroviral therapy or greater than 300 cells per μL (and with undetectable viral load before randomisation) if they were receiving antiretroviral therapy; participants with latent tuberculosis infection were eligible if they had completed at least 5 months of isoniazid preventive therapy, unless they had completed treatment for tuberculosis disease within 3 years before randomisation. Participants were randomly assigned (1:1) in blocks of four by randomly generated sequence to receive two intradermal injections of either MVA85A or placebo. Randomisation was stratified by antiretroviral therapy status and study site. Participants, nurses, investigators, and laboratory staff were masked to group allocation. The second (booster) injection of MVA85A or placebo was given 6-12 months after the first vaccination. The primary study outcome was safety in all vaccinated participants (the safety analysis population). Safety was assessed throughout the trial as defined in the protocol. Secondary outcomes were immunogenicity and vaccine efficacy against Mycobacterium tuberculosis infection and disease, assessed in the per-protocol population. Immunogenicity was assessed in a subset of participants at day 7 and day 28 after the first and second vaccination, and M tuberculosis infection and disease were assessed at the end of the study. The trial is registered with ClinicalTrials.gov, number NCT01151189. Findings: Between Aug 4, 2011, and April 24, 2013, 650 participants were enrolled and randomly assigned; 649 were included in the safety analysis (324 in the MVA85A group and 325 in the placebo group) and 645 in the per-protocol analysis (320 and 325). 513 (71%) participants had CD4 counts greater than 300 cells per μL and were receiving antiretroviral therapy; 136 (21%) had CD4 counts above 350 cells per μL and had never received antiretroviral therapy. 277 (43%) had received isoniazid prophylaxis before enrolment. Solicited adverse events were more frequent in participants who received MVA85A (288 [89%]) than in those given placebo (235 [72%]). 34 serious adverse events were reported, 17 (5%) in each group. MVA85A induced a significant increase in antigen 85A-specific T-cell response, which peaked 7 days after both vaccinations and was primarily monofunctional. The number of participants with negative QuantiFERON-TB Gold In-Tube findings at baseline who converted to positive by the end of the study was 38 (20%) of 186 in the MVA85A group and 40 (23%) of 173 in the placebo group, for a vaccine efficacy of 11·7% (95% CI -41·3 to 44·9). In the per-protocol population, six (2%) cases of tuberculosis disease occurred in the MVA85A group and nine (3%) occurred in the placebo group, for a vaccine efficacy of 32·8% (95% CI -111·5 to 80·3). Interpretation: MVA85A was well tolerated and immunogenic in adults infected with HIV-1. However, we detected no efficacy against M tuberculosis infection or disease, although the study was underpowered to detect an effect against disease. Potential reasons for the absence of detectable efficacy in this trial include insufficient induction of a vaccine-induced immune response or the wrong type of vaccine-induced immune response, or both. Funding: European & Developing Countries Clinical Trials Partnership (IP.2007.32080.002), Aeras, Bill & Melinda Gates Foundation, Wellcome Trust, and Oxford-Emergent Tuberculosis Consortium.